The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / September / ECP 2026: Is HPV-Specific Testing Optimized in Throat Cancer?
Oncology Laboratory management Research and Innovations

ECP 2026: Is HPV-Specific Testing Optimized in Throat Cancer?

Cost and turnaround times are a potential challenge to standardization of testing and optimization of patient pathways

09/14/2026 Video 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Topic Commentary

Share

3 Topic Commentaries

ECP 2026: Is HPV-Specific Testing Optimized in Throat Cancer?

ECP 2026: Is HPV-Specific Testing Optimized in Throat Cancer?

  • Carole Fakhry, MD, MPH
    Carole Fakhry, MD, MPH, MD, MPH

    Otolaryngology–Head and Neck Surgery

    •

    Johns Hopkins School of Medicine

    Many patients aren’t getting the HPV testing that they need for their doctors to develop the best treatment plans, and others are getting over-tested.

    Source
  • Samip Patel, MD
    Samip Patel, MD, MD

    Otolaryngology–Head and Neck Surgery

    •

    Mayo Clinic (Jacksonville, Florida)

    Liquid biopsy may enable us to diagnose patients with positive circulating tumor DNA up to 6 to 8 months earlier than it appears on imaging.

    Source
  • Catherine Haring, MD
    Catherine Haring, MD, MD

    Otolaryngology–Head and Neck Surgery

    •

    University of Michigan

    We can actually identify DNA from a small tumor at the back of the throat circulating throughout the entire bloodstream.

    Source

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.